Editor's Perspective |
From the Section of Cardiovascular Medicine and the Robert Wood Johnson Clinical Scholars Program, Department of Internal Medicine; Section of Health Policy and Administration, School of Public Health, Yale University School of Medicine; and Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, Conn.
Correspondence to Harlan M. Krumholz, MD, SM, PO Box 208088, New Haven, CT 06520-8088. Email harlan.krumholz{at}yale.edu
Key Words: outcomes research
| Introduction |
|---|
|
|
|---|
Although the exact origins of the term "outcomes research are unclear, Ellwood2 coined the term "outcomes management" in his 1988 Shattuck Lecture, in which he envisioned a future in which patient management would be driven by the experience of how similar patients fared as a consequence of alternative treatments. Clancy and Eisenberg3 marked the entry of outcomes research into the scientific lexicon in 1998 with a classic article in Science that stated that "outcomes research—the study of the end results of health services that takes patients experiences, preferences, and values into account—is intended to provide scientific evidence relating to decisions made by all who participate in health care." This elegant definition is both simple and profound. Outcomes research seeks to inform decisions and to hold pre-eminent the perspective of patients and the public. By saying that the research should assist those who participate in health care, they emphasize the needs of those who receive, provide, organize, and pay for health care, including the public.
Eisenberg, as Director of the Agency for Healthcare Research and Quality, often quoted Representative John Porters remarks from a 1998 Congressional appropriations hearing. Porter stated, "What we really want to get at is not how many reports have been done, but how many peoples lives are being bettered by what has been accomplished."4 Eisenberg frequently used the quote to emphasize the need for questions about what research has accomplished, and by extension, what our efforts in health care and public health have produced to improve peoples lives. The implicit message was that the assessment of our success depended on our knowledge of what is important to those we seek to help.
The vision of outcomes research crystallized from the sense that, amid the growing complexity of medical care and the health care system, research was needed to guide practice and policy by focusing attention on the experience of patients and the public. The growing body of work that questioned the safety, effectiveness, efficiency, equity, patient-centeredness, and timeliness of current strategies to promote health and health care was leading to calls for increased accountability and innovation. At its core, outcomes research is a domain in which the convergence of multiple disciplines is applied to generate knowledge of proximate and tangible importance to the delivery and organization of health care. In this Editors Perspective, I would like to specifically address some of the common misunderstandings about outcomes research.
| Myth: Outcomes Research is a Singular Discipline |
|---|
|
|
|---|
| Myth: Outcomes Research is Defined by Its Focus on Secondary Data Analysis |
|---|
|
|
|---|
The articles already published in the first 3 issues of this journal illustrate the breadth of methodologies used. We have published retrospective observational studies,5–10 prospective observational studies,11–14 randomized trials,15–18 an economic analysis,18 surveys,19,20 and a meta-analysis.21 Moreover, we anticipate publishing qualitative studies and other methodological approaches.
Among these methodologies, there is no clear hierarchy in approach.22 Although randomized trials are often considered the best methodological approach in clinical research, this view derives from a narrow perception of the type of knowledge being sought. For studies of the efficacy of an intervention that attempts to minimize bias, a double-blind randomized trial may be the best approach. However, if the goal is to examine variation in practice, an observational design is the only way to address how care differs and what patterns may ultimately be in the best interests of patients. To describe costs of care, economic studies of actual practice are clearly superior to clinical trials in which patient management is often dictated by complex protocols that bear little resemblance to real-world clinical care. To study areas of practice that involve patient–doctor interactions, or to identify new factors that may be associated with better care and clinical outcomes,23 a qualitative design might be optimal. In the selection of a study design, it is important to characterize the question and choose a methodology based on the strengths, weaknesses, and feasibility of all alternatives.
| Myth: Outcomes Research is About "T2" Translational Research |
|---|
|
|
|---|
| Myth: Outcomes Research is a Fad |
|---|
|
|
|---|
The foundation for outcomes research in the area of cardiovascular disease and stroke has strengthened, due in large part to the support of the American Heart Association (AHA). The Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke annual conference, which will celebrate its 10th year in 2009, attracts >600 attendees annually and serves as a venue for collaboration and advancement of the latest methods in the field. The AHA Quality of Care and Outcomes Research Interdisciplinary Group, now an AHA Council, enables the outcomes community to participate formally in the AHA governance structure, support trainees, and lead important statements relevant to advancing cardiovascular health. In addition, Circulation: Cardiovascular Quality and Outcomes was established to promote the best values of outcomes research and serve as a vehicle to publish exemplary scholarship.
With regard to funding, the 4 recently established AHA Outcomes Research Centers, with support of more than $10 million, provide a strong infrastructure at national universities. The trainee positions supplement other training opportunities through the Robert Wood Johnson Clinical Scholars Program, the National Heart, Lung, and Blood Institute (NHLBI) Training Centers, and the Veterans Administration. Importantly, each center has the capacity to offer training to the next generation of outcomes researchers.
The AHA, however, is not the only organization to recognize the need and importance of outcomes research. The NHLBI formed a working group to set priorities in outcomes research and is committed to funding meritorious work in this field. The promise of electronic health records to yield powerful research insight is being harnessed by groups such as the NHLBI-funded Cardiovascular Research Network. The Agency for Healthcare Research and Quality has long demonstrated its commitment to outcomes research in the form of training programs and grants. Hospitals and health care systems are also investing in research institutes that can be internal resources as well as prominent national and international contributors. Industry provides an additional source of funding, although potential conflicts of interest need to be managed.
| Summary |
|---|
|
|
|---|
| Acknowledgments |
|---|
None.
| References |
|---|
|
|
|---|
2. Ellwood PM. Shattuck lecture—outcomes management: a technology of patient experience. N Engl J Med. 1988; 318: 1549–1556.[Medline]
3. Clancy CM, Eisenberg JM. Outcomes research: measuring the end results of health care. Science. 1998; 282: 245–246.
4. Hearing before a subcommittee of the Committee on Appropriations. One Hundred Fifth Congress, Second Session, Part 3. Washington, DC: Department of Health and Human Services; 1998.
5. Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, Chow T. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes. 2009; 2: 16–24.
6. Concannon TW, Griffith JL, Kent DM, Normand S-LT, Newhouse JP, Atkins J, Beshansky JR, Selker HP. Elapsed time in emergency medical services for patients with cardiac complaints: are some patients at greater risk for delay? Circ Cardiovasc Qual Outcomes. 2009; 2: 9–15.
7. Keenan PS, Normand S-LT, Lin Z, Drye EE, Bhat KR, Ross JS, Schuur JD, Stauffer BD, Bernheim SM, Epstein AJ, Wang Y-F, Herrin J, Chen J, Federer JJ, Mattera JA, Wang Y, Krumholz HM. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes. 2008; 1: 29–37.
8. Nallamothu BK, Lu X, Vaughan-Sarrazin MS, Cram P. Coronary revascularization at specialty cardiac hospitals and peer general hospitals in black Medicare beneficiaries. Circ Cardiovasc Qual Outcomes. 2008; 1: 116–122.
9. Norris CM, Spertus JA, Jensen L, Johnson J, Hegadoren KM, Ghali WA, for the APPROACH Investigators. Sex and gender discrepancies in health-related quality of life outcomes among patients with established coronary artery disease. Circ Cardiovasc Qual Outcomes. 2008; 1: 123–130.
10. Pasquali SK, Hall M, Slonim AD, Jenkins KJ, Marino BS, Cohen MS, Shah SS. Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease. Circ Cardiovasc Qual Outcomes. 2008; 1: 74–83.
11. Arnold SV, Decker C, Ahmad H, Olabiyi O, Mundluru S, Reid KJ, Soto GE, Gansert S, Spertus JA. Converting the informed consent from a perfunctory process to an evidence-based foundation for patient decision making. Circ Cardiovasc Qual Outcomes. 2008; 1: 21–28.
12. Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, Mosse F, Jackson JD, Steg PG, Bhatt DL; on behalf of the REACH Registry Investigators. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008; 1: 38–45.
13. Parashar S, Rumsfeld JS, Reid KJ, Buchanan D, Dawood N, Khizer S, Lichtman JH, Vaccarino V. Women, depression, and outcome of myocardial infarction. Circ Cardiovasc Qual Outcomes. 2009; 2: 33–40.
14. Wilson PWF, Pencina M, Jacques P, Selhub J, D'Agostino RSr, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008; 1: 92–97.
15. Arnold SV, Morrow DA, Wang K, Lei Y, Mahoney EM, Scirica BM, Braunwand E, Cohen DJ; on behalf of the MERLIN-TIMI 36 Investigators. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes. 2008; 1: 107–115.
16. Mosca L, Mochari H, Liao M, Christian AH, Edelman DJ, Aggarwal B, Oz MC. A novel family-based intervention trial to improve heart health—FIT Heart: results of a randomized controlled trial. Circ Cardiovasc Qual Outcomes. 2008; 1: 98–106.
17. Orth-Gomér K, Schneiderman N, Wang H, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Womens Intervention Trial for Coronary Heart Disease. Circ Cardiovasc Qual Outcomes. 2009; 2: 25–32.
18. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG; on behalf of the Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008; 1: 12–20.
19. Angell SY, Garg RK, Gwynn RC, Bash L, Thorpe LE, Frieden TR. Prevalence, awareness, treatment, and predictors of control of hypertension in New York City. Circ Cardiovasc Qual Outcomes. 2008; 1: 46–53.
20. Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999–2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009; 2: 41–48.
21. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008; 1: 84–91.
22. Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: is there a rigid hierarchy? Circulation. 2008; 118: 1675–1684.
23. Bradley EH, Curry LA, Webster TR, Mattera JA, Roumanis SA, Radford MJ, McNamara RL, Barton BA, Berg DN, Krumholz HM. Achieving rapid door-to-balloon times: how top hospitals improve complex clinical systems. Circulation. 2006; 113: 1079–1085.
24. Woolf SH. The meaning of translational research and why it matters. JAMA. 2008; 299: 211–213.
This article has been cited by other articles:
![]() |
E. M. Antman and E. D. Peterson Tools for Guiding Clinical Practice From the American Heart Association and the American College of Cardiology: What Are They and How Should Clinicians Use Them? Circulation, March 10, 2009; 119(9): 1180 - 1185. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Home | Subscriptions | Archives | Feedback | Authors | Help | Circulation Journals Home | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |